These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 8043860)

  • 1. Detection of cytarabine resistance in patients with acute myelogenous leukemia using flow cytometry.
    Lacombe F; Belloc F; Dumain P; Puntous M; Makhoul PC; Saux MC; Bernard P; Boisseau MR; Reiffers J
    Blood; 1994 Aug; 84(3):716-23. PubMed ID: 8043860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Detection of the resistance to Ara-C blast cells in acute myeloid leukemia using flow cytometry].
    Lacombe F; Belloc F; Dumain P; Puntous M; Cony-Makhoul P; Bernard P; Boisseau MR; Reiffers J
    Bull Cancer; 1995; 82(5):349-56. PubMed ID: 7626842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.
    Löwenberg B; Suciu S; Archimbaud E; Haak H; Stryckmans P; de Cataldo R; Dekker AW; Berneman ZN; Thyss A; van der Lelie J; Sonneveld P; Visani G; Fillet G; Hayat M; Hagemeijer A; Solbu G; Zittoun R
    J Clin Oncol; 1998 Mar; 16(3):872-81. PubMed ID: 9508168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of rhGM-CSF on Ara-C sensitivity of patients with acute myeloid leukemia in relapse: a flow cytometry study.
    Lacombe F; Puntous M; Dumain P; Cony-Makhoul P; Belloc F; Bernard P; Boisseau M; Reiffers J
    Leuk Res; 1996 Jun; 20(6):481-9. PubMed ID: 8709620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell cycle perturbations in acute myeloid leukemia samples following in vitro exposures to therapeutic agents.
    Banker DE; Groudine M; Willman CL; Norwood T; Appelbaum FR
    Leuk Res; 1998 Mar; 22(3):221-39. PubMed ID: 9619914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multidrug resistant cells with high proliferative capacity determine response to therapy in acute myeloid leukemia.
    te Boekhorst PA; Löwenberg B; van Kapel J; Nooter K; Sonneveld P
    Leukemia; 1995 Jun; 9(6):1025-31. PubMed ID: 7541095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia.
    Bishop JF; Matthews JP; Young GA; Szer J; Gillett A; Joshua D; Bradstock K; Enno A; Wolf MM; Fox R; Cobcroft R; Herrmann R; Van Der Weyden M; Lowenthal RM; Page F; Garson OM; Juneja S
    Blood; 1996 Mar; 87(5):1710-7. PubMed ID: 8634416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multidrug resistance expression and proliferative studies in poor risk acute myeloid leukemia treated with the FLAG (G-CSF plus fludarabine and Ara-C) regimen.
    Tafuri A; De Felice L; Petrucci MT; Mascolo MG; Ricciardi MR; Ciliberti C; Martelli MP; Petti MC
    Cytokines Mol Ther; 1995 Dec; 1(4):301-7. PubMed ID: 9384683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia.
    Clavio M; Venturino C; Pierri I; Garrone A; Miglino M; Canepa L; Balleari E; Balocco M; Michelis GL; Ballerini F; Gobbi M
    Ann Hematol; 2004 Nov; 83(11):696-703. PubMed ID: 15322763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship of [3H]Ara-C incorporation and response to therapy with high-dose Ara-C in AML patients: a Leukemia Intergroup study.
    Raza A; Gezer S; Anderson J; Lykins J; Bennett J; Browman G; Goldberg J; Larson R; Vogler R; Preisler HD
    Exp Hematol; 1992 Nov; 20(10):1194-200. PubMed ID: 1426099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The selective use of AMSA following high-dose cytarabine in patients with acute myeloid leukaemia in relapse: a Leukemia Intergroup study.
    Larson RA; Day RS; Azarnia N; Bennett JM; Browman G; Goldberg J; Gottlieb A; Grunwald H; Miller K; Raza A
    Br J Haematol; 1992 Oct; 82(2):337-46. PubMed ID: 1419816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Long-term outcomes of homoharringtonine, cytarabine, daunorubicin or idarubicin (HAD/HAI) as induction chemotherapy in de novo acute myeloid leukemia].
    Qin T; Xu Z; Zhang Y; Lin Y; Ru K; Fang L; Zhang H; Pan L; Hu N; Qu S; Wang J; Xing R; Xiao Z
    Zhonghua Xue Ye Xue Za Zhi; 2016 Feb; 37(2):94-9. PubMed ID: 27014976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro resistance to cytosine arabinoside, not to daunorubicin, is associated with the risk of relapse in de novo acute myeloid leukaemia.
    Klumper E; Ossenkoppele GJ; Pieters R; Huismans DR; Loonen AH; Rottier A; Westra G; Veerman AJ
    Br J Haematol; 1996 Jun; 93(4):903-10. PubMed ID: 8703824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blasts from elderly acute myeloid leukemia patients are characterized by low levels of culture- and drug-induced apoptosis.
    Garrido SM; Cooper JJ; Appelbaum FR; Willman CL; Kopecky K; Banker DE
    Leuk Res; 2001 Jan; 25(1):23-32. PubMed ID: 11137557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretreatment leukaemia cell drug resistance is correlated to clinical outcome in acute myeloid leukaemia.
    Nørgaard JM; Langkjer ST; Palshof T; Pedersen B; Hokland P
    Eur J Haematol; 2001 Mar; 66(3):160-7. PubMed ID: 11350484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia.
    Schneider C; Oellerich T; Baldauf HM; Schwarz SM; Thomas D; Flick R; Bohnenberger H; Kaderali L; Stegmann L; Cremer A; Martin M; Lohmeyer J; Michaelis M; Hornung V; Schliemann C; Berdel WE; Hartmann W; Wardelmann E; Comoglio F; Hansmann ML; Yakunin AF; Geisslinger G; Ströbel P; Ferreirós N; Serve H; Keppler OT; Cinatl J
    Nat Med; 2017 Feb; 23(2):250-255. PubMed ID: 27991919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Problems related to resistance to cytarabine in acute myeloid leukemia.
    Cros E; Jordheim L; Dumontet C; Galmarini CM
    Leuk Lymphoma; 2004 Jun; 45(6):1123-32. PubMed ID: 15359991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry.
    Guerci A; Merlin JL; Missoum N; Feldmann L; Marchal S; Witz F; Rose C; Guerci O
    Blood; 1995 Apr; 85(8):2147-53. PubMed ID: 7536492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose cytosine arabinoside and daunorubicin induction therapy for adult patients with de novo non M3 acute myelogenous leukemia: impact of cytogenetics on achieving a complete remission.
    Stein AS; O'Donnell MR; Slovak ML; Nademanee A; Dagis A; Schmidt GM; Parker PM; Snyder DS; Smith EP; Somlo G; Margolin KA; Arber D; Niland J; Forman SJ
    Leukemia; 2000 Jul; 14(7):1191-6. PubMed ID: 10914541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effects of G-CSF, GM-CSF and IL-3 on cytosine arabinoside- and daunorubicin-mediated cytotoxicity of acute myeloid leukemia cells and normal myeloid progenitors.
    Waga K; Furusawa S; Nagashima S; Saito K; Shishido H
    Int J Hematol; 1992 Aug; 56(1):17-27. PubMed ID: 1391803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.